MedTrace Logo

[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis

NCT02700763 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-05-06

No results posted yet for this study

Summary

In this feasibility study, \[18F\]dabrafenib will be used as radioactive tracer. All patients in this study are diagnosed with advanced melanoma with evidence of brain metastases and are eligible for treatment with dabrafenib, a specific V600-mutated BRAF inhibitor. Patients will undergo a dynamic PET scan of the brain to determine \[18F\]dabrafenib distribution and kinetics in brain metastases. In addition, a static total body PET scan will be performed to visualize whole body distribution and tracer uptake.

Conditions

Interventions

OTHER

[18F]dabrafenib molecular imaging

A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Geke AP Hospers, MD, PhD · University Medical Center Groningen

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-06
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700763 on ClinicalTrials.gov